SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3039349005> ?p ?o ?g. }

Showing items 1 to 100 of ±204 with 100 items per page.

W3039349005 endingPage "800" @default.
W3039349005 startingPage "788" @default.
W3039349005 abstract "BackgroundEvidence for the effectiveness of treatments in early-onset psychosis is sparse. Current guidance for the treatment of early-onset psychosis is mostly extrapolated from trials in adult populations. The UK National Institute for Health and Care Excellence has recommended evaluation of the clinical effectiveness and cost-effectiveness of antipsychotic drugs versus psychological intervention (cognitive behavioural therapy [CBT] and family intervention) versus the combination of these treatments for early-onset psychosis. The aim of this study was to establish the feasibility of a randomised controlled trial of antipsychotic monotherapy, psychological intervention monotherapy, and antipsychotics plus psychological intervention in adolescents with first-episode psychosis.MethodsWe did a multicentre pilot and feasibility trial according to a randomised, single-blind, three-arm, controlled design. We recruited participants from seven UK National Health Service Trust sites. Participants were aged 14–18 years; help-seeking; had presented with first-episode psychosis in the past year; were under the care of a psychiatrist; were showing current psychotic symptoms; and met ICD-10 criteria for schizophrenia, schizoaffective disorder, or delusional disorder, or met the entry criteria for an early intervention for psychosis service. Participants were assigned (1:1:1) to antipsychotics, psychological intervention (CBT with optional family intervention), or antipsychotics plus psychological intervention. Randomisation was via a web-based randomisation system, with permuted blocks of random size, stratified by centre and family contact. CBT incorporated up to 26 sessions over 6 months plus up to four booster sessions, and family intervention incorporated up to six sessions over 6 months. Choice and dose of antipsychotic were at the discretion of the treating consultant psychiatrist. Participants were followed up for a maximum of 12 months. The primary outcome was feasibility (ie, data on trial referral and recruitment, session attendance or medication adherence, retention, and treatment acceptability) and the proposed primary efficacy outcome was total score on the Positive and Negative Syndrome Scale (PANSS) at 6 months. Primary outcomes were analysed by intention to treat. Safety outcomes were reported according to as-treated status, for all patients who had received at least one session of CBT or family intervention, or at least one dose of antipsychotics. The study was prospectively registered with ISRCTN, ISRCTN80567433.FindingsOf 101 patients referred to the study, 61 patients (mean age 16·3 years [SD 1·3]) were recruited from April 10, 2017, to Oct 31, 2018, 18 of whom were randomly assigned to psychological intervention, 22 to antipsychotics, and 21 to antipsychotics plus psychological intervention. The trial recruitment rate was 68% of our target sample size of 90 participants. The study had a low referral to recruitment ratio (around 2:1), a high rate of retention (51 [84%] participants retained at the 6-month primary endpoint), a high rate of adherence to psychological intervention (defined as six or more sessions of CBT; in 32 [82%] of 39 participants in the monotherapy and combined groups), and a moderate rate of adherence to antipsychotic medication (defined as at least 6 consecutive weeks of exposure to antipsychotics; in 28 [65%] of 43 participants in the monotherapy and combined groups). Mean scores for PANSS total at the 6-month primary endpoint were 68·6 (SD 17·3) for antipsychotic monotherapy (6·2 points lower than at randomisation), 59·8 (13·7) for psychological intervention (13·1 points lower than at randomisation), and 62·0 (15·9) for antipsychotics plus psychological intervention (13·9 points lower than at randomisation). A good clinical response at 6 months (defined as ≥50% improvement in PANSS total score) was achieved in four (22%) of 18 patients receiving antipsychotic monotherapy, five (31%) of 16 receiving psychological intervention, and five (29%) of 17 receiving antipsychotics plus psychological intervention. In as-treated groups, serious adverse events occurred in eight [35%] of 23 patients in the combined group, two [13%] of 15 in the antipsychotics group, four [24%] of 17 in the psychological intervention group, and four [80%] of five who did not receive any treatment. No serious adverse events were considered to be related to participation in the trial.InterpretationThis trial is the first to show that a head-to-head clinical trial comparing psychological intervention, antipsychotics, and their combination is safe in young people with first-episode psychosis. However, the feasibility of a larger trial is unclear because of site-specific recruitment challenges, and amendments to trial design would be needed for an adequately powered clinical and cost-effectiveness trial that provides robust evidence.FundingNational Institute for Health Research. Evidence for the effectiveness of treatments in early-onset psychosis is sparse. Current guidance for the treatment of early-onset psychosis is mostly extrapolated from trials in adult populations. The UK National Institute for Health and Care Excellence has recommended evaluation of the clinical effectiveness and cost-effectiveness of antipsychotic drugs versus psychological intervention (cognitive behavioural therapy [CBT] and family intervention) versus the combination of these treatments for early-onset psychosis. The aim of this study was to establish the feasibility of a randomised controlled trial of antipsychotic monotherapy, psychological intervention monotherapy, and antipsychotics plus psychological intervention in adolescents with first-episode psychosis. We did a multicentre pilot and feasibility trial according to a randomised, single-blind, three-arm, controlled design. We recruited participants from seven UK National Health Service Trust sites. Participants were aged 14–18 years; help-seeking; had presented with first-episode psychosis in the past year; were under the care of a psychiatrist; were showing current psychotic symptoms; and met ICD-10 criteria for schizophrenia, schizoaffective disorder, or delusional disorder, or met the entry criteria for an early intervention for psychosis service. Participants were assigned (1:1:1) to antipsychotics, psychological intervention (CBT with optional family intervention), or antipsychotics plus psychological intervention. Randomisation was via a web-based randomisation system, with permuted blocks of random size, stratified by centre and family contact. CBT incorporated up to 26 sessions over 6 months plus up to four booster sessions, and family intervention incorporated up to six sessions over 6 months. Choice and dose of antipsychotic were at the discretion of the treating consultant psychiatrist. Participants were followed up for a maximum of 12 months. The primary outcome was feasibility (ie, data on trial referral and recruitment, session attendance or medication adherence, retention, and treatment acceptability) and the proposed primary efficacy outcome was total score on the Positive and Negative Syndrome Scale (PANSS) at 6 months. Primary outcomes were analysed by intention to treat. Safety outcomes were reported according to as-treated status, for all patients who had received at least one session of CBT or family intervention, or at least one dose of antipsychotics. The study was prospectively registered with ISRCTN, ISRCTN80567433. Of 101 patients referred to the study, 61 patients (mean age 16·3 years [SD 1·3]) were recruited from April 10, 2017, to Oct 31, 2018, 18 of whom were randomly assigned to psychological intervention, 22 to antipsychotics, and 21 to antipsychotics plus psychological intervention. The trial recruitment rate was 68% of our target sample size of 90 participants. The study had a low referral to recruitment ratio (around 2:1), a high rate of retention (51 [84%] participants retained at the 6-month primary endpoint), a high rate of adherence to psychological intervention (defined as six or more sessions of CBT; in 32 [82%] of 39 participants in the monotherapy and combined groups), and a moderate rate of adherence to antipsychotic medication (defined as at least 6 consecutive weeks of exposure to antipsychotics; in 28 [65%] of 43 participants in the monotherapy and combined groups). Mean scores for PANSS total at the 6-month primary endpoint were 68·6 (SD 17·3) for antipsychotic monotherapy (6·2 points lower than at randomisation), 59·8 (13·7) for psychological intervention (13·1 points lower than at randomisation), and 62·0 (15·9) for antipsychotics plus psychological intervention (13·9 points lower than at randomisation). A good clinical response at 6 months (defined as ≥50% improvement in PANSS total score) was achieved in four (22%) of 18 patients receiving antipsychotic monotherapy, five (31%) of 16 receiving psychological intervention, and five (29%) of 17 receiving antipsychotics plus psychological intervention. In as-treated groups, serious adverse events occurred in eight [35%] of 23 patients in the combined group, two [13%] of 15 in the antipsychotics group, four [24%] of 17 in the psychological intervention group, and four [80%] of five who did not receive any treatment. No serious adverse events were considered to be related to participation in the trial. This trial is the first to show that a head-to-head clinical trial comparing psychological intervention, antipsychotics, and their combination is safe in young people with first-episode psychosis. However, the feasibility of a larger trial is unclear because of site-specific recruitment challenges, and amendments to trial design would be needed for an adequately powered clinical and cost-effectiveness trial that provides robust evidence." @default.
W3039349005 created "2020-07-10" @default.
W3039349005 creator A5000177470 @default.
W3039349005 creator A5004165162 @default.
W3039349005 creator A5005098821 @default.
W3039349005 creator A5005196290 @default.
W3039349005 creator A5005242492 @default.
W3039349005 creator A5011590099 @default.
W3039349005 creator A5013162603 @default.
W3039349005 creator A5013242358 @default.
W3039349005 creator A5015012105 @default.
W3039349005 creator A5019095577 @default.
W3039349005 creator A5020317853 @default.
W3039349005 creator A5020641348 @default.
W3039349005 creator A5020794861 @default.
W3039349005 creator A5021712415 @default.
W3039349005 creator A5025066696 @default.
W3039349005 creator A5025803212 @default.
W3039349005 creator A5026291972 @default.
W3039349005 creator A5029491452 @default.
W3039349005 creator A5029652042 @default.
W3039349005 creator A5030418835 @default.
W3039349005 creator A5031546089 @default.
W3039349005 creator A5032233929 @default.
W3039349005 creator A5032266169 @default.
W3039349005 creator A5036455348 @default.
W3039349005 creator A5037897077 @default.
W3039349005 creator A5040039902 @default.
W3039349005 creator A5043868130 @default.
W3039349005 creator A5044603055 @default.
W3039349005 creator A5046197811 @default.
W3039349005 creator A5048040829 @default.
W3039349005 creator A5048110653 @default.
W3039349005 creator A5050643863 @default.
W3039349005 creator A5053708270 @default.
W3039349005 creator A5053994186 @default.
W3039349005 creator A5054014410 @default.
W3039349005 creator A5055298582 @default.
W3039349005 creator A5055886512 @default.
W3039349005 creator A5056740773 @default.
W3039349005 creator A5058434373 @default.
W3039349005 creator A5059135549 @default.
W3039349005 creator A5071084140 @default.
W3039349005 creator A5073116047 @default.
W3039349005 creator A5074731029 @default.
W3039349005 creator A5074884532 @default.
W3039349005 creator A5075456935 @default.
W3039349005 creator A5080330837 @default.
W3039349005 creator A5081975399 @default.
W3039349005 creator A5082417373 @default.
W3039349005 creator A5088701123 @default.
W3039349005 creator A5091868001 @default.
W3039349005 date "2020-09-01" @default.
W3039349005 modified "2023-10-01" @default.
W3039349005 title "Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study" @default.
W3039349005 cites W1947835636 @default.
W3039349005 cites W1963587466 @default.
W3039349005 cites W1981012777 @default.
W3039349005 cites W2037554578 @default.
W3039349005 cites W2039360026 @default.
W3039349005 cites W2054035563 @default.
W3039349005 cites W2054256216 @default.
W3039349005 cites W2078394222 @default.
W3039349005 cites W2119763231 @default.
W3039349005 cites W2122841140 @default.
W3039349005 cites W2130607817 @default.
W3039349005 cites W2140606211 @default.
W3039349005 cites W2153356230 @default.
W3039349005 cites W2156177125 @default.
W3039349005 cites W2167664297 @default.
W3039349005 cites W2168244593 @default.
W3039349005 cites W2594582101 @default.
W3039349005 cites W2608194486 @default.
W3039349005 cites W2762520970 @default.
W3039349005 cites W2765462713 @default.
W3039349005 cites W2766310000 @default.
W3039349005 cites W2877101308 @default.
W3039349005 cites W2886339749 @default.
W3039349005 cites W3012467444 @default.
W3039349005 cites W3038230700 @default.
W3039349005 doi "https://doi.org/10.1016/s2215-0366(20)30248-0" @default.
W3039349005 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7606914" @default.
W3039349005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32649925" @default.
W3039349005 hasPublicationYear "2020" @default.
W3039349005 type Work @default.
W3039349005 sameAs 3039349005 @default.
W3039349005 citedByCount "45" @default.
W3039349005 countsByYear W30393490052020 @default.
W3039349005 countsByYear W30393490052021 @default.
W3039349005 countsByYear W30393490052022 @default.
W3039349005 countsByYear W30393490052023 @default.
W3039349005 crossrefType "journal-article" @default.
W3039349005 hasAuthorship W3039349005A5000177470 @default.
W3039349005 hasAuthorship W3039349005A5004165162 @default.
W3039349005 hasAuthorship W3039349005A5005098821 @default.
W3039349005 hasAuthorship W3039349005A5005196290 @default.
W3039349005 hasAuthorship W3039349005A5005242492 @default.
W3039349005 hasAuthorship W3039349005A5011590099 @default.